EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,911 other subscribers.

To burn or not to burn?

I once wrote a post about Pancreatic NET “to cut or not to cut”.  You can read that here.  Surgery for small pancreatic NETs remains controversial with most guidelines and study guidelines recommending surveillance for small primary tumours less than 2cm.  There are exceptions to that, e.g. preventative surgery if the tumour is threatening important vessels and for functional cases where the surgery is palliative in nature.  Contrast that against some patient perspectives where they just want it cut out (and some will ‘surgeon-shop’ until they find someone who will).

Most pancreatic NET are lower grades (e.g. Grade 1 and 2) well differentiated, most are non-functional, many are localised.  Functional tumours such as Insulinoma are mostly small and localised. 

A lack of sensitive and specific markers that can predict the patients most likely to have tumours that will grow and/or metastasise is still a work in progress, it’s a tough call as the biological behavior of an individual PNET remains unpredictable.

The Hippocratic oath can often guide doctors (and guideline writers) as radical surgery can present considerable morbidity (and a small risk of mortality) which might harm the patient more than the tumour. 

Pancreatic NETs are growing as a research topic and in 2022, I noticed an increase in studies suggesting ablation as a method of removing sporadic small pancreatic NETs which is less risky and reduces the chance of severe morbidity but has comparable efficiency.  The technique is not new but is not normally used in pancreatic NET cases.  As science progresses, so will ablation techniques.  But is there enough data to make this a standard of care? 

I followed this thread on Twitter following the publishing of a small study as mentioned above.  I witnessed the differing views.  The author is known for pragmatism and often plays ‘devil’s advocate’ to provoke discussion (I’m sure he won’t mind me taking that view!)

Ablation vs Surveillance

I followed a thread on Twitter (see below) following the publishing of a small study as mentioned above.  I witnessed the differing views, although the author is known for pragmatism and often plays ‘devil’s advocate’ to provoke discussion (I’m sure he won’t mind me taking that view!).  The first graphic below is the thread comprising a tweet in 3 parts and then some comments from those following the thread in the second graphic.  As you can see there it’s just as controversial as the surgery vs surveillance issue.   One thing that was generally agreed was the need for more studies to confirm this is a viable option. 

The study was suggesting Endoscopic Ultrasound (EUS) guided ethanol ablation, but other studies stick to EUS-guided radiofrequency ablation (RFA).  I will attach samples of both below. 

The final comment mentions a study (ASPEN) that I have already published indicating there is clinical evidence that surveillance is the best option in most cases.  You can read that by clicking here.

Comparison of EUS-guided ablation and surgical resection for non-functioning small pancreatic neuroendocrine tumors: a propensity score matching study

Hoonsub So, M.D., Sung Woo Ko, M.D., PhD., Seung Hwan Shin, M.D., Eun Ha Kim, R.N., Jimin Son, M.D., SuHyun Ha, M.D., Ki Byung Song, M.D. PhD., Hwa Jung Kim, M.D. PhD., Myung-Hwan Kim, M.D., PhD., Do Hyun Park, M.D., Ph.D. PII: DOI: Reference: S0016-5107(22)02141-1 YMGE 13469

Click here

EUS-RFA for Pancreatic Insulinoma

This study conclusion is interesting.


EUS-RFA is safer than surgery and highly effective for the treatment of PI. If confirmed in a randomized study, EUS-RFA treatment can become first line therapy for sporadic PI.

Read the article abstract by clicking here

EUS-RFA of the pancreas: where are we and future directions

Gollapudi LA, Tyberg A. EUS-RFA of the pancreas: where are we and future directions. Transl Gastroenterol Hepatol. 2022 Apr 25;7:18. doi: 10.21037/tgh-2020-11. PMID: 35548478; PMCID: PMC9081919. 

Click here


I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. 

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.   

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,911 other subscribers.

Thanks for reading.


I’m also active on Facebook. Like this page.
I’m also active on this Facebook page. Follow this page.
Also like this awareness page on Facebook. 

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


A spotlight on Chromogranin A

What is Chromogranin A? Chromogranin A (CgA) is an acidic protein released along with catecholamines from chromaffin cells and nerve terminals. This statement alone might

Read More »

Neuroendocrine Cancer: Catch them early, not late!

Diagnosing Neuroendocrine Neoplasms (NENs). It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can

Read More »

A spotlight on Rectal Neuroendocrine Neoplasms

What are Rectal NENs Rectal Neuroendocrine Neoplasms (NENs) (rNENs) account for approximately 1-2% of all primary cancers in the rectum.  The other main cancer types

Read More »
Clinical Trial

Clinical Trial: Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

A new clinical trial post. What is Terbium-161 (161Tb-DOTA-LM3) (Beta plus). Terbium-161 is a radioactive substance.  DOTA-LM3 is a novel somatostatin antagonist targeted using somatostatin

Read More »

Repeat after me: Maria Menounos has Neuroendocrine Cancer

Like many people from outside USA, I don’t really know anything about Maria Menounos.  For those in the same boat, let me confirm she is

Read More »

Summary of April 2023 on RonnyAllan.NET

Summary of RonnyAllan.NET website activity in April 2023 The top 10 most read posts in April are included below as the main product of this summary

Read More »

A spotlight on 5-HIAA

Background. It’s important to note that not every type of Neuroendocrine Neoplasm will get the same tests due to the heterogenous nature of this cancer type.

Read More »

The NET Detectives

The NET Detectives is an awareness post. Detecting NETs In general, it’s probably true to say that Neuroendocrine Tumours (NETs) are difficult to diagnose. Some

Read More »

Low FODMAPs – The NET Effect

Background Many people with NET have had issues prior to diagnosis and then continue to have similar issues after. For some it will be either

Read More »
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,911 other subscribers.

2 thoughts on “EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

  • Margaret Rimland

    Love that you wrote about this, it’s kinda my crusade. I see so many of the small PNET crowd going for pancreatic surgery instead of surveillance and wish the ablation option would be presented to them. Surgeons don’t even know it’s an option. I was lucky enough to consult with several surgeons about my small PNET and one of them seemed particularly interested in my case, was similar in age to me, lived nearby, etc. I asked him what he thought about ablation and he said he didn’t know anything but he’d ask the Interventional Radiologist that he was friends with. He called me the next day and said, gee, it’s totally possible, he’ll do it, no biggie. Give him a call. I haven’t actually done it because of the ASPEN study and other doctors said it wasn’t necessary, plus not many IR’s have experience. I think I’m going to do it anyway. Tired of wondering if this thing is sitting there metastasizing, as are most of the small PNET crew.

I love comments - feel free!

%d bloggers like this: